Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team led by scientists at the University of Oxford and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie in Berlin has used fluorescent versions of next-generation diabetes and obesity drugs to reveal, for the first time, exactly which cells they target in the pancreas and brain.

daLUXendins can be visualized using fluorescence microscopy to pinpoint GLP1R and GIPR binding and activation. This is shown in the periphery (islet of Langerhans in the pancreas, left) and centrally (hypothalamus in the brain, right) where daLUXendins act to drive insulin secretion and to control appetite, respectively.
daLUXendins can be visualized using fluorescence microscopy to pinpoint GLP1R and GIPR binding and activation. This is shown in the periphery (islet of Langerhans in the pancreas, left) and centrally (hypothalamus in the brain, right) where daLUXendins act to drive insulin secretion and to control appetite, respectively.

Drugs like Ozempic and Wegovy mimic a natural hormone called GLP-1 to lower blood sugar and reduce appetite. A newer medicine, Mounjaro (tirzepatide), goes one step further, activating two hormone receptors — GLP-1 and GIP — and delivering greater benefits for both glucose control and weight loss. However, until now, scientists did not fully understand which cells and brain circuits made this possible.

The research team developed fluorescent versions of these dual-target drugs, known as daLUXendins. These probes behave like the real medicines but also light up under a microscope, allowing researchers to track them in fine detail.
In studies on mice, the team discovered that daLUXendins targeted a wider range of pancreatic cells than single-target drugs — not just insulin-producing beta cells, but also alpha and delta cells, which communicate with beta cells to regulate blood sugar. In the brain, the glowing drugs reached regions that control appetite and even lit up metabolite-sensing cells called tanycytes, which send signals about hunger.

'Dual agonists aren't just more powerful because they act on two receptors,' said Professor David Hodson, Radcliffe Department of Medicine, University of Oxford. 'They also reach a broader network of cells, which may be key to their superior effects.'

 

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Researchers from the Nuffield Department of Primary Care Health Sciences contribute to parliamentary calls for overhaul of obesity care

Research from the Health Behaviors team has informed a series of parliamentary reports calling for urgent action to tackle obesity in England.

Oxford University invites 100,000 people to take part in a major study of plant-based diets

Researchers at the Nuffield Department of Population Health have launched a major new study designed to generate the most up-to-date picture of different diets in the UK, including plant-based diets, and how they affect long-term health and wellbeing.

Look beyond my skin: your psoriasis could help us understand who develops psoriatic arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

Professor Matthew Wood receives BioUK Special Recognition Award 2026

Professor Matthew Wood, Director and Chief Scientific Officer of the Oxford-Harrington Rare Disease Centre (OHC), has received BioUK’s Special Recognition Award 2026 for his contribution to rare disease research, therapeutic development and the wider life sciences sector.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE).